Zhao Runzhi, Xu Xiyuan, Sun Li, Zhang Guohua
Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Anesthesiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Front Oncol. 2023 Jan 13;12:960299. doi: 10.3389/fonc.2022.960299. eCollection 2022.
Clinical and experimental evidence suggested that anesthesia choice can influence cancer progression and patients' outcomes by modulating tumor microenvironment and tumorigenic pathways. Curative resection is the mainstay of therapy for hepatocellular carcinoma (HCC), which is an intractable disease due to high recurrence and poor prognosis. However, different anesthetics may play different roles in alleviating surgery-induced stress response and inflammatory cytokines release that are considered to be closely associated with proliferation, invasion and metastasis of tumor cells. Propofol, sevoflurane, non-steroidal anti-inflammatory drugs and local anesthetics have shown to exert anti-tumor effect on HCC mainly through regulating microRNAs or signaling pathways, while other inhalational agents, dexmedetomidine and opioids have the potential to promote tumor growth. In terms of anesthetic methods and analgesia strategies, propofol based total intravenous anesthesia and thoracic epidural analgesia could be preferred for HCC patients undergoing open liver resection rather than inhalational anesthesia. Local anesthesia techniques have great potential to attenuate perioperative stress response, hence they may contribute to more favorable outcomes. This review summarized the relations between different anesthesia choices and HCC patients' long-term outcomes as well as their underlying mechanisms. Due to the complexity of molecules interactions and signaling pathways, further studies are warranted to confirm these results so as to optimize anesthesia strategy for HCC patients.
临床和实验证据表明,麻醉选择可通过调节肿瘤微环境和致瘤途径来影响癌症进展和患者预后。根治性切除是肝细胞癌(HCC)治疗的主要手段,由于其高复发率和不良预后,HCC是一种难治性疾病。然而,不同的麻醉剂在减轻手术引起的应激反应和炎症细胞因子释放方面可能发挥不同作用,而这些反应被认为与肿瘤细胞的增殖、侵袭和转移密切相关。丙泊酚、七氟醚、非甾体抗炎药和局部麻醉药已显示出主要通过调节微小RNA或信号通路对HCC发挥抗肿瘤作用,而其他吸入性麻醉剂、右美托咪定和阿片类药物则有可能促进肿瘤生长。在麻醉方法和镇痛策略方面,对于接受开放性肝切除的HCC患者,基于丙泊酚的全静脉麻醉和胸段硬膜外镇痛可能比吸入麻醉更可取。局部麻醉技术在减轻围手术期应激反应方面具有巨大潜力,因此可能有助于获得更有利的结果。本综述总结了不同麻醉选择与HCC患者长期预后之间的关系及其潜在机制。由于分子相互作用和信号通路的复杂性,有必要进行进一步研究以证实这些结果,从而优化HCC患者的麻醉策略。